focus -WSS

focus

author：fashion 2025-09-28 22:52:58 - browse：1

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The boys, now 6, who are gene therapy’s ‘edge case’ problem

knowledge

focus

WSS

FDA approves first treatment for ultra

Beware the threat of staffing cuts at the CDC

Readout Newsletter: Merck, Vertex, and Viking updates

Steward Health Care has deal to sell doctor network to UnitedHealth

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Washington mulls new rules to avert another Change Healthcare

hotspot

focus

hotspot

Alkermes shareholders re

FDA's naming rule on biosimilars has undermined competition

Anesthesiologist group: stop taking Ozempic before surgery

Liz Cheney makes 1st public comment since Trump's election interference indictments

Dobbs anniversary: the lost opportunity of abortion as health care

States should stop sabotaging methadone treatment reform

In Memoriam: Notable people who died in 2023

Food as medicine: Medically tailored meals may get standardized

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The pain doctors face in trying to build their families

explore

Why the world’s most expensive drug might be worth the price

Decaf coffee targeted by food safety group under obscure FDA rule

Scientists boost immune system in aging mice by making it youthful

FDA approves first treatment for ultra

Baltimore teen accused of firing into crowd during block party mass shooting

Oprah kicked off a national conversation on obesity. Let's have it

knowledge

focus

focus

hotspot